AYTU BioScience, Inc. - Form 8-K Summary
Business Context and Reporting Period
AYTU BioScience, Inc. (NASDAQ: AYTU), a Delaware corporation, filed this Current Report on Form 8-K on March 10, 2020. The filing discloses the entry into a material definitive agreement regarding a registered direct offering of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a securities purchase agreement to raise capital through a registered direct offering. Key transaction metrics include:
- Aggregate Gross Proceeds: Approximately $9.0 million (before deducting placement agent fees and offering expenses).
- Common Stock Issued: 4,450,000 shares at a purchase price of $1.15 per share.
- Pre-Funded Warrants Issued: Warrants to purchase up to 3,376,087 shares of Common Stock at an effective price of $1.15 per share ($1.1499 paid at closing, $0.0001 upon exercise).
- Placement Agent Fees: 7.5% of aggregate gross proceeds plus a 1.0% management fee.
- Placement Agent Warrants: Warrants to purchase up to 508,696 shares at an exercise price of $1.4375 per share, expiring five years from the effective date.
The filing does not provide specific figures for revenue, profit, cash flow, margins, or existing debt levels, as this report focuses solely on the capital raise transaction.
Material Changes and Outlook
This transaction represents a material change in the Company's capital structure and liquidity position. The offering is expected to close on or about March 13, 2020, subject to customary closing conditions. The proceeds are intended to fund the Company's operations and strategic initiatives, though specific allocation details are not provided in this filing. The Company engaged H.C. Wainwright & Co., LLC as the exclusive placement agent.
Investor Verification Checklist
- Verify the closing date of the offering (expected March 13, 2020) and the actual net proceeds received after fees.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Confirm the dilution impact of the 4,450,000 shares and 3,376,087 pre-funded warrants on existing shareholders.
- Monitor the exercise terms of the Placement Agent Warrants (508,696 shares at $1.4375).
- Check subsequent filings for the use of proceeds and any updates to the Company's liquidity position.